LABD vs TZA

Key Takeaways

• Both LABD and TZA are daily -3x inverse leveraged exchange-traded funds (ETFs) issued by Direxion that seek opposite daily performance of their benchmarks before fees and expenses.
• LABD provides targeted exposure to the biotechnology sector through the equal-weighted S&P Biotechnology Select Industry Index, while TZA offers broad small-capitalization exposure via the market-cap-weighted Russell 2000 Index.
• Expense ratios stand at 1.07% for LABD and 0.99% for TZA, reflecting the higher costs associated with derivatives-based leveraged strategies.
• Both funds employ swap agreements and other derivatives with daily rebalancing, making them suitable primarily for short-term trading rather than buy-and-hold positions due to compounding effects over multiple periods.
• LABD concentrates risk within a single high-volatility industry, whereas TZA spreads exposure across numerous small-cap sectors including healthcare, financials, and industrials.
• Structural differences position the ETFs as complementary rather than direct competitors for investors seeking inverse exposure to distinct segments of the U.S. equity market.

Introduction

Investors seeking short-term inverse exposure to specific areas of the U.S. equity market often turn to leveraged ETFs such as LABD and TZA. These funds do not compete directly; instead, they deliver alternative bearish strategies targeting different segments—one focused on the biotechnology industry and the other on the broader small-capitalization universe. In the current environment of shifting interest rate expectations and sector rotations, understanding their structural distinctions helps investors align positioning with particular market views or risk-management objectives.

Direxion Daily S&P Biotech Bear 3X ETF (LABD) Overview

The Direxion Daily S&P Biotech Bear 3X ETF seeks daily investment results, before fees and expenses, of 300% of the inverse (opposite) of the performance of the S&P Biotechnology Select Industry Index. This modified equal-weighted index measures the biotechnology sub-industry based on Global Industry Classification Standards (GICS). The fund maintains its -3x daily target through a portfolio of swap agreements and other derivatives that are rebalanced at the close of each trading day. It holds a small number of positions consisting primarily of cash equivalents and collateral alongside the derivative contracts. The net expense ratio is 1.07%. As a non-diversified, leveraged inverse product, LABD delivers concentrated exposure to biotechnology companies and carries elevated volatility relative to unleveraged sector funds.

Direxion Daily Small Cap Bear 3X ETF (TZA) Overview

The Direxion Daily Small Cap Bear 3X ETF seeks daily investment results, before fees and expenses, of 300% of the inverse of the performance of the Russell 2000 Index. This market-capitalization-weighted benchmark tracks approximately 2,000 small-capitalization companies drawn from the Russell 3000 Index. Like its counterpart, TZA achieves its -3x daily objective through swaps and derivatives subject to daily rebalancing. Portfolio holdings consist mainly of cash and collateral instruments supporting the derivative positions. The net expense ratio is 0.99%. The fund provides broad-based inverse exposure across small-cap sectors such as healthcare, financials, industrials, and information technology, resulting in a more diversified risk profile than single-sector leveraged products.

Industry and Thematic Backdrop

Both ETFs operate within the broader U.S. equity landscape where small-capitalization companies and biotechnology firms respond differently to macroeconomic drivers. Small-cap equities often exhibit greater sensitivity to domestic economic growth, interest rate changes, and credit conditions. Biotechnology companies face additional influences from clinical trial outcomes, regulatory approvals, research and development spending, and capital market access for funding. Recent market cycles have highlighted volatility in both areas stemming from shifts in monetary policy and investor risk appetite. Capital flows into or out of small caps and healthcare innovation themes can amplify price movements, creating environments where inverse leveraged products may serve tactical roles for short-term positioning.

Performance and Positioning Comparison

In recent market cycles, both funds have demonstrated high volatility consistent with their -3x daily leverage and daily reset mechanisms. LABD tends to experience sharper moves tied to biotechnology-specific news flow and sector rotation within healthcare. TZA reflects broader small-cap dynamics, including earnings trends across multiple industries and overall economic sentiment. Relative positioning depends on whether investors anticipate weakness concentrated in biotechnology or across the small-cap universe. The daily rebalancing of both products means longer-term holding periods can produce returns that diverge significantly from the simple multiple of benchmark performance due to compounding and volatility drag.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Tickeron AI Verdict

Based on observable structural factors, Tickeron’s AI would currently assign a modest probabilistic preference to TZA. Its slightly lower expense ratio, broader diversification across small-cap sectors, and longer operating history provide a marginally more balanced risk profile for tactical inverse exposure compared with the concentrated biotechnology focus of LABD. Investors should evaluate these characteristics against their specific market outlook and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations